Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Policy Reversal: FDA Will No Longer Require Suffixes For Older Biologics

Mar 07 2019

• By Michael Cipriano

the word suffix on cubes

Related Content

US FDA's Biosimilars Chief Leah Christl Plans Departure

Jan 11 2019

US FDA Biosimilars Staff Faces More Transition As Sue Lim Departs After Christl

Feb 25 2019

Novel Biologics Will Get Suffixes (Or At Least One Did)

Nov 16 2017

FDA Biosimilar Naming Policy Takes Middle-Of-The-Road Approach

Aug 27 2015

Novel Biologics In US Might Not Start Getting Suffixes Until August

Apr 05 2017

Biosimilar Name Debate Heats Up As USP Says <em>Zarxio</em> Doesn't Need Suffix

Jan 25 2016

FDA's Biologics Naming Plan: Industry Wants 'Memorable' Suffixes

Nov 09 2015

Established Biologics Do Not Require Name Change, AbbVie Says

Nov 09 2015

FDA Biosimilar Naming Proposal Pits Providers, Patients Against Insurers, Pharmacies

Nov 16 2015

Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’

Jan 13 2017

AbbVie Looks To White House For Relief From US FDA Naming Guidance

Feb 16 2017

FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say

Feb 16 2017

Related Companies

AbbVie Inc.

Ultragenyx Pharmaceutical Inc.

Amgen, Inc.

Additional Topics

United States Biosimilars Biologics Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window